Global Infectious Enteritis Treatment Market 2022-2026

Global Infectious Enteritis Treatment Market 2022-2026

Technavio has been monitoring the infectious enteritis treatment market and it is poised to grow by $ 403.92 mn during 2022-2026, progressing at a CAGR of 5.09% during the forecast period. Our report on the infectious enteritis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing geriatric population, the growing population with irritable bowel syndrome (IBS) and diarrhea, and rising research and development activities.

The infectious enteritis treatment market analysis includes the route of administration segment and geographic landscape.

Technavio's infectious enteritis treatment market is segmented as below:

By Route of Administration

• Oral
• Injections

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the burgeoning demand for antivirals as one of the prime reasons driving the infectious enteritis treatment market growth during the next few years. Also, increasing FDA approvals of infectious enteritis treatment drugs, and increasing focus on healthcare infrastructure will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the infectious enteritis treatment market covers the following areas:

• Infectious enteritis treatment market sizing
• Infectious enteritis treatment market forecast
• Infectious enteritis treatment market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading infectious enteritis treatment market vendors that include Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Viatris Inc. Also, the infectious enteritis treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Companies Mentioned

Abbott Laboratories, Almirall SA, Cipla Ltd., Zydus Lifesciences Ltd., F. Hoffmann La Roche Ltd., Galderma SA, GlaxoSmithKline Plc, Hetero Healthcare Ltd., Mayne Pharma Group Ltd., Medimetriks Pharmaceuticals Inc., Merck KGaA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., Viatris Inc.